The X-GRAFFETM Clinical-Scale Cell Selection System

BioMag is commercializing its Clinical-Scale Cell Separation system called X-GRAFFE (eXternal GRAdient FerroFluid-Enabled).  X-GRAFFETM is a patent-pending immunomagnetic cell selection system.  X-GRAFFE leverages the key properties of BioMag’s proprietary 5th generation ferrofluids (highly magnetic colloidal nanoparticles functionalized with binding agents). that have highly rapid binding kinetics, biocompatibility and a magnetic moment that enables cell separation using external magnetic gradients.  X-GRAFFETM enables cell separations to be performed in a closed system using inexpensive, single-use components.  The X-GRAFFETM cell selection platform is appropriate for a wide range of clinical applications, e.g., the manufacture of CAR-T cell & gene therapy products.

Employing BioMag’s common-capture ferrofluids, X-GRAFFE can isolate target cells with very high purity, excellent viability and unmatched cell yields.  For example, X-GRAFFE has been used to gently and rapidly isolate CD3+ cells from leukapheresis products with 97% purity, 98% viability, and 93.1% yield.

X-GRAFFE can also be used to select T cell subsets (e.g., CD4+ and CD8+ cells), regulatory T cells (Tregs), NK cells, CD34+ stem cells and for depleting unwanted cells from cellular products (e.g., removing T cells from purified stem cell products to prevent GVHD).  X-GRAFFE can also perform negative cell selections for cell products requiring untouched cells and cell subsets.  BioMag is currently developing a releasable ferrofluid for X-GRAFFETM to permit particle-free CGT product manufacture.